In 2013, Sun et al reported the CSC biomarkers CD133 and ABCG2 in EpCAM-positive CTCs in 82 patients with hepatocellular carcinoma [70], and they identified the nuclear localization of β-catenin in 10 of 17 of these patients with EpCAM-positive CTCs. Here, EPCAM is linked to hepatocellular carcinoma.